Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 6/20 | 1.00 |
| ▸ | CA7 | P43166 | 6/20 | 1.00 |
| ▸ | CA9 | Q16790 | 6/20 | 1.00 |
| ▸ | CA14 | Q9ULX7 | 6/20 | 1.00 |
| ▸ | CA1 | P00915 | 5/20 | 1.00 |
| ▸ | CA2 | P00918 | 4/20 | 1.00 |
| ▸ | TYR | P14679 | 3/20 | 1.00 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.67 |
| ▸ | AKR1B10 | O60218 | 4/20 | 0.66 |
| ▸ | AKR1B1 | P15121 | 4/20 | 0.66 |
| ▸ | TTR | P02766 | 1/20 | 0.66 |
| ▸ | APP | P05067 | 1/20 | 0.66 |
| ▸ | MAOB | P27338 | 1/20 | 0.62 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.62 |
| ▸ | GLO1 | Q04760 | 1/20 | 0.62 |
| ▸ | CAMK2A | Q9UQM7 | 1/20 | 0.62 |
| ▸ | MMP2 | P08253 | 2/20 | 0.62 |
| ▸ | MMP9 | P14780 | 2/20 | 0.62 |
| ▸ | MMP13 | P45452 | 1/20 | 0.62 |
| ▸ | ESR1 | P03372 | 2/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Methyl P-Hydroxycinnamate SCHEMBL895938 | 1.00 | CA12 (1.00) | CA12CA7CA9CA14CA1 | |
| Methyl P-Hydroxycinnamate SCHEMBL30463538 | 1.00 | CA12 (1.00) | CA12CA7CA9CA14CA1 | |
| Methyl P-Hydroxycinnamate SCHEMBL28386655 | 1.00 | CA12 (1.00) | CA12CA7CA9CA14CA1 | |
| Methyl P-Hydroxycinnamate SCHEMBL28876782 | 0.96 | CA12 (0.93) | CA12CA7CA9CA14CA1 | |
| SCHEMBL404485 | 0.94 | CA12 (0.89) | CA12CA7CA9CA14CA1 | |
| SCHEMBL404484 | 0.94 | CA12 (0.89) | CA12CA7CA9CA14CA1 | |
| SCHEMBL71224 | 0.92 | CA12 (0.84) | CA12CA7CA9CA14CA1 | |
| SCHEMBL5057418 | 0.92 | CA12 (0.84) | CA12CA7CA9CA14CA1 | |
| SCHEMBL16024183 | 0.91 | CA12 (0.83) | CA12CA7CA9CA14CA1 | |
| SCHEMBL17061331 | 0.91 | CA12 (0.83) | CA12CA7CA9CA14CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1195 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119875442-B | Fluorocarbon powder coating and preparation method thereof | 金华市大友谊塑粉科技有限公司 | 2025-06-03 | — | — | CN | claimed |
| CN-119326786-B | High-resistance starch composition for improving diabetes and preparation method thereof | 中国热带农业科学院热带生物技术研究所 | 2025-05-23 | — | — | CN | claimed |
| CN-119875442-A | Fluorocarbon powder coating and preparation method thereof | 金华市大友谊塑粉科技有限公司 | 2025-04-25 | — | — | CN | claimed |
| CN-119390573-A | Hydroxycinnamic acid derivative and preparation method and application thereof | 重庆医科大学 | 2025-02-07 | — | — | CN | claimed |
| CN-119326786-A | High-resistance starch composition for improving diabetes and preparation method thereof | 中国热带农业科学院热带生物技术研究所 | 2025-01-21 | — | — | CN | claimed |
| CN-118666843-A | Quinolone-lixiviated histone deacetylase inhibitor and preparation method and application thereof | 天津市医药科学研究所(天津市医药与健康研究中心) | 2024-09-20 | — | — | CN | claimed |
| CN-118084732-A | 5-HTT/HDAC targeted double-target inhibitor and preparation method and application thereof | 杭州师范大学 | 2024-05-28 | — | — | CN | claimed |
| CN-117942328-A | Application of methyl 4-hydroxy cinnamate in preparation of medicines for treating inflammatory diseases | 新乡医学院 | 2024-04-30 | — | — | CN | claimed |
| CN-117924281-A | Reversible light response compound, preparation method and application thereof, self-assembly system, graphene composition and photoelectric functional device | 中国石油化工股份有限公司 | 2024-04-26 | — | — | CN | claimed |
| CN-117304043-A | Esmolol hydrochloride and preparation of preparation thereof | 杭州沐源生物医药科技有限公司 | 2023-12-29 | — | — | CN | claimed |
| CN-104356087-A | Novel nitric oxide donor type HDAC (histone deacetylase) inhibitor as well as preparation method and medical application thereof | AFFILIATED HOSPITAL OF NANTONG UNIV | 2015-02-18 | — | — | CN | claimed |
| US-8784930-B2 | Transparent conductive film having high optical transmittance and method for manufacturing the same | FAR EASTERN NEW CENTURY CORPORATION (TW) | 2014-07-22 | — | — | US | claimed |
| US-20120080218-A1 | TRANSPARENT CONDUCTIVE FILM HAVING HIGH OPTICAL TRANSMITTANCE AND METHOD FOR MANUFACTURING THE SAME | FAR EASTERN NEW CENTURY CORPORATION (TW) | 2012-04-05 | — | — | US | claimed |
| EP-0980203-B1 | ANTIMICROBIAL PREVENTION AND TREATMENT OF HUMAN IMMUNEDEFICIENCY VIRUS AND OTHER INFECTIOUS DISEASES | SQUIRES MERYL (US) | 2007-04-04 | — | — | EP | claimed |
| EP-0980203-A4 | ANTIMICROBIAL PREVENTION AND TREATMENT OF HUMAN IMMUNEDEFICIENCY VIRUS AND OTHER INFECTIOUS DISEASES | SQUIRES MERYL (US) | 2004-05-06 | — | — | EP | claimed |
| US-20030104082-A1 | Antimicrobial prevention and treatment of human immunedeficience virus and other infectious diseases | MCGINLEY PARTNERS, LLC (US) | 2003-06-05 | — | — | US | claimed |
| EP-0980203-A1 | ANTIMICROBIAL PREVENTION AND TREATMENT OF HUMAN IMMUNEDEFICIENCY VIRUS AND OTHER INFECTIOUS DISEASES | Squires, Meryl (US) | 2000-02-23 | — | — | EP | claimed |
| WO-1998042188-A1 | ANTIMICROBIAL PREVENTION AND TREATMENT OF HUMAN IMMUNEDEFICIENCY VIRUS AND OTHER INFECTIOUS DISEASES | SQUIRES MERYL (US) | 1998-10-01 | — | — | WO | claimed |
| US-5243021-A | Polylactam, polyester, polyether copolymers containing stilbene groups | LEVER BROTHERS COMPANY, DIVISION OF CONOPCO, INC. (US) | 1993-09-07 | — | — | US | claimed |
| EP-0003461-B1 | AMINOALCOHOL DERIVATIVES OF ORTHO-HYDROXY-METHYL CINNAMATE, PROCESS FOR THEIR PREPARATION AND MEDICINES CONTAINING THEM | LIPHA, LYONNAISE INDUSTRIELLE PHARMACEUTIQUE (FR) | 1981-04-29 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030104082-A1 | Antimicrobial prevention and treatment of human immunedeficience virus and other infectious diseases | CD14, CD59, SLC19A1 | CA12 3378/4885CA7 3310/4885CA9 2899/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.